Market Cap 3.51B
Revenue (ttm) 0.00
Net Income (ttm) -177.81M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 6,509,300
Avg Vol 1,537,066
Day's Range N/A - N/A
Shares Out 79.14M
Stochastic %K 52%
Beta 0.40
Analysts Strong Sell
Price Target $49.62

Company Profile

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. The company's clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. It has initiated a Phase 2...

Industry: Biotechnology
Sector: Healthcare
Phone: 888 378 6240
Address:
150 N. Radnor Chester Rd., Suite F200, Radnor, United States
PrivateProfiteer
PrivateProfiteer Nov. 15 at 10:02 AM
$MLYS: The last close is $40.85, showing a neutral market context as the RSI is at 50.61, indicating no overbought or oversold conditions. The price is below the 30-day moving average (MA30) of $41.39 but above the 50-day moving average (MA50) of $40.17, suggesting a potential for upward movement if it breaks above the MA30. The 60-day high of $47.65 provides a resistance level, while the low of $14.53 indicates a significant range for potential volatility. Directional bias leans slightly bullish due to the proximity to the MA50 and the neutral RSI. Suggested entry is at $41.00, just above the MA30. Set a stop loss at $39.00 to manage risk. Target 1 at $45.00, near the 60D high, and Target 2 at $47.00, slightly below the 60D high for a conservative exit. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 15 at 1:26 AM
$MLYS is currently trading at $44.29, showing a bullish market context with an RSI of 60.44, indicating upward momentum but nearing overbought territory. The price is above both the 30-day MA of 41.3 and the 50-day MA of 40.05, suggesting a strong bullish trend. The recent 60-day high of 47.65 provides a potential resistance level, while the low of 14.29 indicates significant volatility. For a trade plan, consider entering at $44.50, slightly above the last close to confirm upward movement. Set a stop loss at $41.00, just below the 30-day MA for protection against potential reversals. Target 1 can be set at $47.00, approaching the 60-day high, while Target 2 can be at $48.00, allowing for a breakout scenario. This plan aligns with the current bullish sentiment, supported by the RSI and moving averages. https://privateprofiteers.com
0 · Reply
medguy
medguy Nov. 14 at 4:24 PM
$MLYS and $DGNX looking for reversal
0 · Reply
Arcides
Arcides Nov. 14 at 3:09 PM
$MLYS standed good yesterday but today is falling on high volume.
0 · Reply
_www_larval_com_
_www_larval_com_ Nov. 14 at 2:42 PM
$SGML 17%[10%] $CMBM 12%[16%] $MLYS 9%[-12%] $AVXL 9%[-34%] $TSSI -8%[-41%] most notable movement within the first minutes of trading.
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 4:58 AM
$MLYS is currently trading at $44.29, showing a bullish market context with an RSI of 60.44, indicating upward momentum but nearing overbought territory. The price is above both the 30-day MA of 41.3 and the 50-day MA of 40.05, suggesting a strong bullish trend. The recent 60-day high of 47.65 provides a potential resistance level, while the low of 14.29 indicates significant volatility. For a trade plan, consider entering at $44.50, slightly above the last close to confirm upward movement. Set a stop loss at $41.00, just below the 30-day MA for protection against potential reversals. Target 1 can be set at $47.00, approaching the 60-day high, while Target 2 can be at $48.00, allowing for a breakout scenario. This plan aligns with the current bullish sentiment, supported by the RSI and moving averages. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 3:05 AM
$MLYS: The current market context shows a last close of $47.11, near the 60D high of $47.42, indicating bullish momentum. The RSI at 62.73 suggests the stock is approaching overbought territory, but it still has room for further upside before a potential reversal. The MA30 at $40.92 and MA50 at $39.46 indicate a strong upward trend, as the price is significantly above these moving averages. Directional bias is bullish given the proximity to the 60D high and the positive trend indicated by the moving averages. Suggested entry is at $47.15, just above the last close to capture potential upward movement. A stop loss can be set at $44.24, below the MA30, to manage risk. Targets: first target at $48.50, just above the 60D high, and a second target at $50.00, which is a psychological level. This plan leverages current bullish momentum while managing risk effectively. https://privateprofiteers.com
0 · Reply
JarvisFlow
JarvisFlow Nov. 12 at 11:46 AM
HC Wainwright & Co. updates rating for Mineralys Therapeutics ( $MLYS ) to Buy, target set at 52 → 56.
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 2:40 AM
$MLYS: The current market context shows a last close of $47.11, near the 60D high of $47.42, indicating bullish momentum. The RSI at 62.73 suggests the stock is approaching overbought territory, but it still has room for further upside before a potential reversal. The MA30 at $40.92 and MA50 at $39.46 indicate a strong upward trend, as the price is significantly above these moving averages. Directional bias is bullish given the proximity to the 60D high and the positive trend indicated by the moving averages. Suggested entry is at $47.15, just above the last close to capture potential upward movement. A stop loss can be set at $44.24, below the MA30, to manage risk. Targets: first target at $48.50, just above the 60D high, and a second target at $50.00, which is a psychological level. This plan leverages current bullish momentum while managing risk effectively. https://privateprofiteers.com
0 · Reply
JarvisFlow
JarvisFlow Nov. 11 at 2:27 PM
Wells Fargo has adjusted their stance on Mineralys Therapeutics ( $MLYS ), setting the rating to Overweight with a target price of 50 → 55.
0 · Reply
Latest News on MLYS
3 Potential Biotech Acquisition Targets

Sep 19, 2025, 12:53 PM EDT - 2 months ago

3 Potential Biotech Acquisition Targets

AZN ETNB INCY SNDX TVTX


Mineralys Therapeutics' blood pressure drug meets goal in trials

Mar 10, 2025, 7:12 AM EDT - 8 months ago

Mineralys Therapeutics' blood pressure drug meets goal in trials


PrivateProfiteer
PrivateProfiteer Nov. 15 at 10:02 AM
$MLYS: The last close is $40.85, showing a neutral market context as the RSI is at 50.61, indicating no overbought or oversold conditions. The price is below the 30-day moving average (MA30) of $41.39 but above the 50-day moving average (MA50) of $40.17, suggesting a potential for upward movement if it breaks above the MA30. The 60-day high of $47.65 provides a resistance level, while the low of $14.53 indicates a significant range for potential volatility. Directional bias leans slightly bullish due to the proximity to the MA50 and the neutral RSI. Suggested entry is at $41.00, just above the MA30. Set a stop loss at $39.00 to manage risk. Target 1 at $45.00, near the 60D high, and Target 2 at $47.00, slightly below the 60D high for a conservative exit. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 15 at 1:26 AM
$MLYS is currently trading at $44.29, showing a bullish market context with an RSI of 60.44, indicating upward momentum but nearing overbought territory. The price is above both the 30-day MA of 41.3 and the 50-day MA of 40.05, suggesting a strong bullish trend. The recent 60-day high of 47.65 provides a potential resistance level, while the low of 14.29 indicates significant volatility. For a trade plan, consider entering at $44.50, slightly above the last close to confirm upward movement. Set a stop loss at $41.00, just below the 30-day MA for protection against potential reversals. Target 1 can be set at $47.00, approaching the 60-day high, while Target 2 can be at $48.00, allowing for a breakout scenario. This plan aligns with the current bullish sentiment, supported by the RSI and moving averages. https://privateprofiteers.com
0 · Reply
medguy
medguy Nov. 14 at 4:24 PM
$MLYS and $DGNX looking for reversal
0 · Reply
Arcides
Arcides Nov. 14 at 3:09 PM
$MLYS standed good yesterday but today is falling on high volume.
0 · Reply
_www_larval_com_
_www_larval_com_ Nov. 14 at 2:42 PM
$SGML 17%[10%] $CMBM 12%[16%] $MLYS 9%[-12%] $AVXL 9%[-34%] $TSSI -8%[-41%] most notable movement within the first minutes of trading.
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 4:58 AM
$MLYS is currently trading at $44.29, showing a bullish market context with an RSI of 60.44, indicating upward momentum but nearing overbought territory. The price is above both the 30-day MA of 41.3 and the 50-day MA of 40.05, suggesting a strong bullish trend. The recent 60-day high of 47.65 provides a potential resistance level, while the low of 14.29 indicates significant volatility. For a trade plan, consider entering at $44.50, slightly above the last close to confirm upward movement. Set a stop loss at $41.00, just below the 30-day MA for protection against potential reversals. Target 1 can be set at $47.00, approaching the 60-day high, while Target 2 can be at $48.00, allowing for a breakout scenario. This plan aligns with the current bullish sentiment, supported by the RSI and moving averages. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 3:05 AM
$MLYS: The current market context shows a last close of $47.11, near the 60D high of $47.42, indicating bullish momentum. The RSI at 62.73 suggests the stock is approaching overbought territory, but it still has room for further upside before a potential reversal. The MA30 at $40.92 and MA50 at $39.46 indicate a strong upward trend, as the price is significantly above these moving averages. Directional bias is bullish given the proximity to the 60D high and the positive trend indicated by the moving averages. Suggested entry is at $47.15, just above the last close to capture potential upward movement. A stop loss can be set at $44.24, below the MA30, to manage risk. Targets: first target at $48.50, just above the 60D high, and a second target at $50.00, which is a psychological level. This plan leverages current bullish momentum while managing risk effectively. https://privateprofiteers.com
0 · Reply
JarvisFlow
JarvisFlow Nov. 12 at 11:46 AM
HC Wainwright & Co. updates rating for Mineralys Therapeutics ( $MLYS ) to Buy, target set at 52 → 56.
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 2:40 AM
$MLYS: The current market context shows a last close of $47.11, near the 60D high of $47.42, indicating bullish momentum. The RSI at 62.73 suggests the stock is approaching overbought territory, but it still has room for further upside before a potential reversal. The MA30 at $40.92 and MA50 at $39.46 indicate a strong upward trend, as the price is significantly above these moving averages. Directional bias is bullish given the proximity to the 60D high and the positive trend indicated by the moving averages. Suggested entry is at $47.15, just above the last close to capture potential upward movement. A stop loss can be set at $44.24, below the MA30, to manage risk. Targets: first target at $48.50, just above the 60D high, and a second target at $50.00, which is a psychological level. This plan leverages current bullish momentum while managing risk effectively. https://privateprofiteers.com
0 · Reply
JarvisFlow
JarvisFlow Nov. 11 at 2:27 PM
Wells Fargo has adjusted their stance on Mineralys Therapeutics ( $MLYS ), setting the rating to Overweight with a target price of 50 → 55.
0 · Reply
OpenOutcrier
OpenOutcrier Nov. 11 at 1:50 PM
$MLYS (-1.8% pre) Form S-3ASR Mineralys Therapeutics, https://ooc.bz/l/84089
0 · Reply
Panban
Panban Nov. 11 at 6:20 AM
$MLYS MINERALYS THERAPEUTICS INC - IN ADDITION, OFFERING OF UP TO $300 MLN OF COMMON STOCK
0 · Reply
d_risk
d_risk Nov. 11 at 12:32 AM
$MLYS - Mineralys Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors MLYS drops risks tied to tariffs, inflation, and economic uncertainty, but flags new threats from potential tax law changes and possible FDA/government agency disruptions that could hit financials, product approvals, and stock value. #Biotechnology #EconomicUncertainty #FDADisruptions #TaxLawChanges #RegulatoryRisk 🟢 Added 🟠 Removed https://d-risk.ai/MLYS/10-Q/2025-11-10
0 · Reply
Jakeipedia
Jakeipedia Nov. 10 at 3:59 PM
$MLYS just the beginning!!
0 · Reply
OpenOutcrier
OpenOutcrier Nov. 10 at 1:43 PM
$MLYS (+2.6% pre) Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025 https://ooc.bz/l/83864
0 · Reply
CrispDry
CrispDry Nov. 7 at 6:11 PM
$MLYS data late November?
0 · Reply
Digger75
Digger75 Nov. 4 at 4:22 PM
0 · Reply
Digger75
Digger75 Oct. 31 at 2:20 PM
$MLYS come on 44
0 · Reply
Digger75
Digger75 Oct. 30 at 6:00 PM
0 · Reply
Doozio
Doozio Oct. 29 at 1:00 PM
$IWM $XBI $KWEB “nobody is bullish enough”. FOOK da GRRR’s. It’s $MLYS TTWO $BILI s. https://youtube.com/shorts/jdaoZHj_2nA?si=HGDp-uv5-kvw0u-2 🐒🍌🧠⏰♾️
0 · Reply
Jakeipedia
Jakeipedia Oct. 24 at 7:02 PM
$MLYS added
1 · Reply
ivanhoff
ivanhoff Oct. 17 at 3:01 PM
Only four stocks on the new 52-week relative strength high list so far this morning - $ELAN $MLYS $ASX $CLS
0 · Reply